✦ LIBER ✦

Overall survival of patients with chemotherapy-naive advanced melanoma treated with ipilimumab 3 mg/kg in clinical trials

✍ Scribed by Dummer, Reinhard; Schadendorf, Dirk; Ascierto, Paolo A; Larkin, James; Lebbé, Celeste; Hauschild, Axel

Book ID: 125401247
Publisher: BioMed Central
Year: 2014
Tongue: English
Weight: 98 KB
Volume: 12
Category: Article
ISSN: 1479-5876
DOI: 10.1186/1479-5876-12-S1-P8

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Pretreatment Serum VEGF Is Associated wi

Pretreatment Serum VEGF Is Associated with Clinical Response and Overall Survival in Advanced Melanoma Patients Treated with Ipilimumab

✍ Yuan, J.; Zhou, J.; Dong, Z.; Tandon, S.; Kuk, D.; Panageas, K. S.; Wong, P.; Wu 📂 Article 📅 2014 🏛 American Association for Cancer Research 🌐 English ⚖ 564 KB

9307 Long-term survival in advanced mela

9307 Long-term survival in advanced melanoma patients treated with ipilimumab at 10 mg/kg: ongoing analyses from completed Phase II trials

✍ Maio, M.; Lebbé, C.; Sileni, V. Chiarion; Siegel, J.; Hoos, A.; Humphrey, R.; O' 📂 Article 📅 2009 🏛 Elsevier Science 🌐 English ⚖ 49 KB

Pre-treatment serum vascular endothelial

Pre-treatment serum vascular endothelial growth factor is associated with clinical response and overall survival in advanced melanoma patients treated with ipilimumab

✍ Jianda Yuan,Jun Zhou,Zhiwan Dong,Sapna Tandon… 📂 Article 📅 2013 🏛 Springer (Biomed Central Ltd.) 🌐 English ⚖ 260 KB

Efficacy and safety of ipilimumab 3mg/kg

Efficacy and safety of ipilimumab 3mg/kg in patients with pretreated, metastatic, mucosal melanoma

✍ Del Vecchio, Michele; Di Guardo, Lorenza; Ascierto, Paolo A.; Grimaldi, Antonio 📂 Article 📅 2014 🏛 Elsevier Science 🌐 English ⚖ 536 KB

9308 Activity of ipilimumab at 10 mg/kg

9308 Activity of ipilimumab at 10 mg/kg in patients with advanced melanoma is independent of baseline prognostic factors

✍ Schadendorf, D.; Wolchok, J.; Neyns, B.; Lebbé, C.; Harmankaya, K.; Verschraegen 📂 Article 📅 2009 🏛 Elsevier Science 🌐 English ⚖ 52 KB

A phase 2 clinical trial of nab-paclitax

A phase 2 clinical trial of nab-paclitaxel in previously treated and chemotherapy-naive patients with metastatic melanoma

✍ Evan M. Hersh; Steven J. O'Day; Antoni Ribas; Wolfram E. Samlowski; Michael S. G 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 234 KB 👁 2 views

## Abstract ## BACKGROUND: __nab__‐Paclitaxel (ABI‐007, Abraxane), a 130‐nM, albumin‐bound (__nab__) particle form of Cremophor‐free paclitaxel, is approved for metastatic breast cancer. In the current study, the efficacy and safety of __nab__‐paclitaxel were evaluated in previously treated and ch